📊 INSP Key Takeaways
Is Inspire Medical Systems, Inc. (INSP) a Good Investment?
Inspire Medical Systems demonstrates strong fundamental improvement with exceptional 86.5% gross margins, 13.6% YoY revenue growth, and near break-even operating margins (-0.5%), indicating a path to profitability. The company maintains fortress-like balance sheet strength with minimal debt (0.03x leverage), excellent liquidity (6.34x current ratio), positive free cash flow, and substantial cash reserves, providing ample runway to reach sustained profitability.
Inspire Medical Systems shows strong underlying fundamentals with double-digit revenue growth, exceptional gross margins, and a very strong balance sheet with minimal leverage and ample liquidity. The business is now meaningfully profitable and free-cash-flow positive, which supports the quality of its growth. The main caution is that operating margin remains relatively modest versus gross margin, and net income materially exceeds operating income, so sustained improvement in core operating profitability remains important to confirm.
Why Buy Inspire Medical Systems, Inc. Stock? INSP Key Strengths
- Exceptional gross margin of 86.5% demonstrates strong pricing power and product-market fit
- Operating margin approaching break-even (-0.5%) with 13.6% YoY revenue growth shows improving operational efficiency
- Fortress balance sheet: minimal debt (0.03x Debt/Equity), $792.3M stockholders equity, $98.9M cash, excellent liquidity ratios
- Significant profitability inflection: net income improved 171.8% YoY despite remaining negative, indicating strong cost control and operating leverage
- Positive free cash flow ($3.1M) despite net losses suggests underlying business viability and cash generation capability
- Revenue growth remains solid at 13.6% year over year while the company has scaled into profitability.
- Gross margin of 85.4% indicates strong pricing power and an attractive device economics profile.
- Balance sheet strength is excellent, with a 6.08x current ratio, very low debt at 0.03x debt-to-equity, and positive free cash flow.
INSP Stock Risks: Inspire Medical Systems, Inc. Investment Risks
- Currently unprofitable at net income level (-$11.3M, -5.5% margin) with negative ROE (-1.4%) and ROA (-1.2%)
- Thin free cash flow margin (1.5%) relative to revenue indicates limited operational cushion and execution sensitivity
- Medical device sector faces intense competition, regulatory complexity, and reimbursement rate pressures
- Dependent on continued market adoption of sleep apnea treatment solutions in competitive landscape
- Capital intensity of medical device manufacturing and distribution could pressure margins if growth slows
- Operating margin is still only 5.6%, implying the business is not yet converting its high gross profit into equally strong core earnings.
- Net income is far above operating income, which may indicate that part of recent earnings strength came from non-core items rather than pure operating leverage.
- Free cash flow margin of 8.6% is positive but still moderate, so cash conversion needs to keep improving as the company grows.
Key Metrics to Watch
- Operating margin progression toward positive territory
- Gross margin stability as revenue scales
- Quarterly net income trend to confirm profitability inflection
- Free cash flow growth and conversion rates
- Revenue growth rate sustainability in core sleep apnea market
- Operating margin expansion and the gap between operating income and net income
- Free cash flow growth and cash conversion as a percentage of revenue
Inspire Medical Systems, Inc. (INSP) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 1.5% FCF margin may limit capital allocation flexibility. Strong liquidity with a 6.34x current ratio provides a solid financial cushion.
INSP Profit Margin, ROE & Profitability Analysis
INSP vs Healthcare Sector: How Inspire Medical Systems, Inc. Compares
How Inspire Medical Systems, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Inspire Medical Systems, Inc. Stock Overvalued? INSP Valuation Analysis 2026
Based on fundamental analysis, Inspire Medical Systems, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Inspire Medical Systems, Inc. Balance Sheet: INSP Debt, Cash & Liquidity
INSP Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Inspire Medical Systems, Inc.'s revenue has grown significantly by 291% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.72 indicates the company is currently unprofitable.
INSP Revenue Growth, EPS Growth & YoY Performance
INSP Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $201.3M | $3.0M | $0.10 |
| Q3 2025 | $203.2M | $3.0M | $0.31 |
| Q2 2025 | $195.9M | -$212.0K | $-0.01 |
| Q1 2025 | $164.0M | $3.0M | $0.10 |
| Q3 2024 | $153.3M | -$8.5M | $-0.29 |
| Q2 2024 | $151.1M | -$212.0K | $-0.01 |
| Q1 2024 | $127.9M | -$10.0M | $-0.34 |
| Q3 2023 | $109.2M | -$8.5M | $-0.29 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Inspire Medical Systems, Inc. Dividends, Buybacks & Capital Allocation
INSP SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Inspire Medical Systems, Inc. (CIK: 0001609550)
📋 Recent SEC Filings
❓ Frequently Asked Questions about INSP
What is the AI rating for INSP?
Inspire Medical Systems, Inc. (INSP) has a Combined AI Rating of BUY from Claude (BUY) and ChatGPT (BUY) with 77% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are INSP's key strengths?
Claude: Exceptional gross margin of 86.5% demonstrates strong pricing power and product-market fit. Operating margin approaching break-even (-0.5%) with 13.6% YoY revenue growth shows improving operational efficiency. ChatGPT: Revenue growth remains solid at 13.6% year over year while the company has scaled into profitability.. Gross margin of 85.4% indicates strong pricing power and an attractive device economics profile..
What are the risks of investing in INSP?
Claude: Currently unprofitable at net income level (-$11.3M, -5.5% margin) with negative ROE (-1.4%) and ROA (-1.2%). Thin free cash flow margin (1.5%) relative to revenue indicates limited operational cushion and execution sensitivity. ChatGPT: Operating margin is still only 5.6%, implying the business is not yet converting its high gross profit into equally strong core earnings.. Net income is far above operating income, which may indicate that part of recent earnings strength came from non-core items rather than pure operating leverage..
What is INSP's revenue and growth?
Inspire Medical Systems, Inc. reported revenue of $204.6M.
Does INSP pay dividends?
Inspire Medical Systems, Inc. does not currently pay dividends.
Where can I find INSP SEC filings?
Official SEC filings for Inspire Medical Systems, Inc. (CIK: 0001609550) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is INSP's EPS?
Inspire Medical Systems, Inc. has a diluted EPS of $-0.39.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is INSP a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Inspire Medical Systems, Inc. has a BUY rating with 77% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is INSP stock overvalued or undervalued?
Valuation metrics for INSP: ROE of -1.4% (sector avg: 15%), net margin of -5.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy INSP stock in 2026?
Our dual AI analysis gives Inspire Medical Systems, Inc. a combined BUY rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is INSP's free cash flow?
Inspire Medical Systems, Inc.'s operating cash flow is $12.8M, with capital expenditures of $9.7M. FCF margin is 1.5%.
How does INSP compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -5.5% (avg: 12%), ROE -1.4% (avg: 15%), current ratio 6.34 (avg: 2).